$ENSC
Ensysce Biosciences, Inc. Stock $ensc

$ensc Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022103 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2021 Q4
Revenue	$279.4K	$207.5K	$1.635M
YoY Change	-76.74%	-53.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.687M	$1.951M	$1.454M
YoY Change	-89.7%	395.38%
% of Gross Profit
Research & Development	$4.756M	$5.311M	$2.188M
YoY Change	177.38%	1046.61%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
% of Gross Profit
Operating Expenses	$6.443M	$7.263M	$3.642M
YoY Change	-64.38%	747.32%	3744.65%
Operating Profit	-$6.163M	-$7.055M
YoY Change	-63.5%	1609.86%
Interest Expense	$4.859K	$37.78K	$1.987M
YoY Change	-100.36%	-95.85%	801.82%
% of Operating Profit
Other Income/Expense, Net	-$3.692M	-$867.9K	-$10.36M
YoY Change	-455.78%	59.26%	-714.65%
Pretax Income	-$9.856M	-$7.923M	-$10.04M
YoY Change	-42.7%	727.38%	-653.98%
Income Tax
% Of Pretax Income
Net Earnings	-$9.856M	-$7.923M	-$10.04M
YoY Change	-42.58%	727.38%	-647.99%
Net Earnings / Revenue	-3528.02%	-3818.9%	-613.77%
Basic Earnings Per Share	-$5.13	-$0.24
Diluted Earnings Per Share	-$5.099M	-$232.3K	-$411.5K
COMMON SHARES
Basic Shares Outstanding	37.32M shares	33.99M shares
Diluted Shares Outstanding	160.7K shares	141.6K shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.503M	$3.735M	$12.26M
YoY Change	-34.22%	-53.39%	24828.33%
Cash & Equivalents	$4.503M	$3.735M	$12.26M
Short-Term Investments
Other Short-Term Assets	$3.018M	$3.184M	$2.956M
YoY Change	51.77%	1074.98%	1777.15%
Inventory
Prepaid Expenses	$2.983M	$3.173M	$2.931M
Receivables	$140.8K	$276.6K	$441.7K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.662M	$7.195M	$15.66M
YoY Change	-14.11%	-13.92%	6816.27%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$627.6K	$671.4K	$754.8K
YoY Change	-21.2%	-19.89%
Total Long-Term Assets	$627.6K	$754.2K	$754.8K
YoY Change	-21.2%	-10.01%	-94.02%
TOTAL ASSETS
Total Short-Term Assets	$7.662M	$7.195M	$15.66M
Total Long-Term Assets	$627.6K	$754.2K	$754.8K
Total Assets	$8.290M	$7.949M	$16.42M
YoY Change	-14.69%	-13.56%	27.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.286M	$3.048M	$301.1K
YoY Change	172.44%	-2.95%	0.37%
Accrued Expenses	$2.272M	$2.681M	$3.432M
YoY Change	-39.62%	535.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$7.553M	$2.520M	$12.75M
YoY Change	170.01%
Total Short-Term Liabilities	$11.91M	$8.248M	$16.48M
YoY Change	69.38%	104.73%	6229.36%
LONG-TERM LIABILITIES
Long-Term Debt	$1.387M	$137.3K	$4.441M
YoY Change	-34.41%		461.23%
Other Long-Term Liabilities	$1.415M	$360.8K	$3.653M
YoY Change	47.82%
Total Long-Term Liabilities	$2.802M	$360.8K	$3.653M
YoY Change	-8.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.91M	$8.248M	$16.48M
Total Long-Term Liabilities	$2.802M	$360.8K	$3.653M
Total Liabilities	$14.71M	$8.747M	$24.58M
YoY Change	49.76%	131.07%	74.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$105.4M	-$95.50M	-$85.85M
YoY Change
Common Stock	$221.00	$3.553K	$2.464K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.094M	-$491.6K	-$7.878M
YoY Change
Total Liabilities & Shareholders Equity	$8.290M	$7.949M	$16.42M
YoY Change	-14.69%	-13.56%	27.72%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2021 Q4
OPERATING ACTIVITIES
Net Income	-$9.856M	-$7.923M	-$10.04M
YoY Change	-42.58%	727.38%	-647.99%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Cash From Operating Activities	-$6.714M	-$4.441M	-$3.768M
YoY Change	75.54%	1058.52%	852.46%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.483M	-265.8K	9.187M
YoY Change	181.43%	-103.25%	-5556.04%
NET CHANGE
Cash From Operating Activities	-6.714M	-4.441M	-3.768M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	7.483M	-265.8K	9.187M
Net Change In Cash	768.4K	-4.706M	5.419M
YoY Change	-165.9%	-160.44%	-126418.41%
FREE CASH FLOW
Cash From Operating Activities	-$6.714M	-$4.441M	-$3.768M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001716947
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2021Q4	us-gaap	Deferred Costs DeferredCosts		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	ENSC	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities		usd
	ENSC	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities		usd
CY2021Q2	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes		usd
	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes		usd
CY2021Q2	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants		usd
	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants		usd
	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount		usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q2	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1		usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1		usd
	us-gaap	Depreciation Depreciation		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Accretion Expense AccretionExpense		usd
	ENSC	Change In Fair Value Of Embedded Derivative ChangeInFairValueOfEmbeddedDerivative		usd
	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants		usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	ENSC	Repayment Insurance Premiums RepaymentInsurancePremiums		usd
	ENSC	Transaction Costs For Business Combination Included In Accounts Payable Offset Against Additional Paidin Capital TransactionCostsForBusinessCombinationIncludedInAccountsPayableOffsetAgainstAdditionalPaidinCapital		usd
	ENSC	Deferred Transaction Costs For Convertible Notes DeferredTransactionCostsForConvertibleNotes		usd
	ENSC	Stockbased Compensation StockbasedCompensation		usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
	ENSC	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision		usd
	us-gaap	Depreciation Depreciation		usd
CY2022Q2	ENSC	Consultant Stock Compensation Expenses ConsultantStockCompensationExpenses		usd
CY2022Q2	ENSC	Stated Interest Accrual StatedInterestAccrual		usd
CY2022Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
CY2021Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38306
	dei	Entity Registrant Name EntityRegistrantName	Ensysce Biosciences, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2755287
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7946 Ivanhoe Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 201
	dei	Entity Address City Or Town EntityAddressCityOrTown	La Jolla
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92037
CY2022Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	276631	usd
CY2021Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	441721	usd
CY2022Q2	ENSC	Operating Lease Right Of Use Current Asset OperatingLeaseRightOfUseCurrentAsset	10251	usd
CY2021Q4	ENSC	Operating Lease Right Of Use Current Asset OperatingLeaseRightOfUseCurrentAsset	24721	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3173246	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2931415	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	7194774	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	15662593	usd
CY2022Q2	us-gaap	Deferred Costs DeferredCosts	82819	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	671423	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	754756	usd
CY2022Q2	us-gaap	Assets Assets	7949016	usd
	dei	City Area Code CityAreaCode	(858)
	dei	Local Phone Number LocalPhoneNumber	263-4196
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Bankruptcy Proceedings Reporting Current EntityBankruptcyProceedingsReportingCurrent	true
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37320556	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3734646	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12264736	usd
CY2021Q4	us-gaap	Assets Assets	16417349	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3048037	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	301104	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2670591	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3407533	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10313	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	24874	usd
CY2022Q2	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	2519539	usd
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	12358886	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	2519539	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	12748155	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8248480	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16481666	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	137317	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4440951	usd
CY2022Q2	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	360797	usd
CY2021Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	3652790	usd
CY2022Q2	us-gaap	Liabilities Liabilities	8746594	usd
CY2021Q4	us-gaap	Liabilities Liabilities	24575407	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35550034	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24662904	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35530279	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24643149	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	3553	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2464	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	95016354	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	77964860	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95511543	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-85845567	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-491636	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7878243	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-305942	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-279815	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-797578	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8158058	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7949016	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16417349	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	207471	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	444516	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	810569	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	695091	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5311298	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	463219	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8451394	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	787595	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1951356	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	393914	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4217161	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	884386	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	7262654	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	857133	usd
	us-gaap	Operating Expenses OperatingExpenses	12668555	usd
	us-gaap	Operating Expenses OperatingExpenses	1671981	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7055183	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-412617	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11857986	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-976890	usd
CY2021Q2	ENSC	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	712899	usd
	ENSC	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	673314	usd
CY2022Q2	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	88763	usd
	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-2678415	usd
CY2022Q2	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	148393	usd
	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	2942791	usd
CY2022Q2	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	892636	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	2595278	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	37781	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	910327	usd
	us-gaap	Interest Expense InterestExpense	52802	usd
	us-gaap	Interest Expense InterestExpense	1258161	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2850	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-347566	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10816	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-347566	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-867937	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-544994	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2983942	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-932413	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-7923120	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-957611	usd
	us-gaap	Profit Loss ProfitLoss	-8874044	usd
	us-gaap	Profit Loss ProfitLoss	-1909303	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-26309	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-22067	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-26127	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-26028	usd
CY2022Q2	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	102479	usd
	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	818059	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7999290	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-935544	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9665976	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1883275	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33988783	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16053550	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30656712	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15943867	shares
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-7303437	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36373	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5696703	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	7695264	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-957611	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5167292	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1111273	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5718689	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	295580	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-7923120	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-797578	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6658427	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	262862	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5696703	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	7695264	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	80193	usd
	us-gaap	Profit Loss ProfitLoss	-1909303	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5167292	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8158058	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8158058	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	54250	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13794032	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2386242	usd
	us-gaap	Profit Loss ProfitLoss	-8874044	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-797578	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-797578	usd
	us-gaap	Profit Loss ProfitLoss	-8874044	usd
	us-gaap	Profit Loss ProfitLoss	-1909303	usd
	us-gaap	Depreciation Depreciation	101	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4500	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	28677	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	312197	usd
	us-gaap	Accretion Expense AccretionExpense	945969	usd
	ENSC	Change In Fair Value Of Embedded Derivative ChangeInFairValueOfEmbeddedDerivative	673314	usd
	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	2942791	usd
	ENSC	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	-2678415	usd
	ENSC	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	347566	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	698013	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	80193	usd
	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	-91	usd
	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	-1177	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	2595278	usd
	ENSC	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	-165090	usd
	ENSC	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	75354	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	158499	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-103245	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2746933	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	347420	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	546841	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-127004	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7877508	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-649461	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4500	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4500	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	50000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	350000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	262862	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	265812	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7804167	usd
	ENSC	Repayment Insurance Premiums RepaymentInsurancePremiums	391270	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-657082	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8467029	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8530090	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7817568	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12264736	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	194214	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3734646	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8011782	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	usd
	ENSC	Transaction Costs For Business Combination Included In Accounts Payable Offset Against Additional Paidin Capital TransactionCostsForBusinessCombinationIncludedInAccountsPayableOffsetAgainstAdditionalPaidinCapital	1200412	usd
	ENSC	Deferred Transaction Costs For Convertible Notes DeferredTransactionCostsForConvertibleNotes	82819	usd
	ENSC	Stockbased Compensation StockbasedCompensation	1742479	usd
	ENSC	Conversions Of Convertible Notes Into Common Stock ConversionsOfConvertibleNotesIntoCommonStock	11198754	usd
	ENSC	Conversions Of Convertible Notes Into Common Stock ConversionsOfConvertibleNotesIntoCommonStock	5696703	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	1068950	usd
	ENSC	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	818059	usd
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_801_eus-gaap--BasisOfAccounting_z4wCp4qS9XLf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_82B_zEHk74C0vf2">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the United States Securities Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the three and six months ended June 30, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2021, which may be found in the Company’s Form 10-K filed with the SEC on March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business Combination</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, LACQ was identified as the acquired company for financial reporting purposes, primarily because the stockholders of Former Ensysce control the majority of the voting power of the combined company, Former Ensysce’s board of directors comprise a majority of the governing body of the combined company, and Former Ensysce’s senior management comprise the leadership of the combined company. Accordingly, for accounting purposes, the transaction was treated as the equivalent of Former Ensysce issuing shares for the net assets of LACQ, accompanied by a recapitalization. The net assets of LACQ, primarily consisting of cash of $<span id="xdx_900_eus-gaap--Cash_iI_pn5n6_c20220630_zrTur9yiL2r3" title="Cash">7.8</span> million and prepaid expenses of $<span id="xdx_90C_eus-gaap--PrepaidExpenseCurrentAndNoncurrent_iI_pn5n6_c20220630_zKjsyHqf85Y2" title="Prepaid expense">1.1</span> million, were recorded at historical cost with no goodwill or other intangible assets recorded. The shares and net loss per share prior to the reverse recapitalization have been retroactively restated to reflect the exchange ratio of <span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220630_zdAGeaqT7iW6" title="Debt Instrument, conversion price">0.06585</span>. The financial statements reflect the historical operations of Ensysce.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not generated any product revenue and had an accumulated deficit of $<span id="xdx_90F_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20220630_zpaWPsn2GT92" title="Accumulated deficit">95.5</span> million at June 30, 2022. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, the Company executed a share subscription facility with an investment group (the “GEM agreement”). Under the agreement, the investor agreed to provide the Company with a share subscription facility of up to $<span id="xdx_901_eus-gaap--CommonStockSharesSubscriptions_iI_pn5n6_c20201231_z062V9veVOc7" title="Common stock, subscriptions value">60.0</span> million for a 36-month term following the public listing of the Company’s common stock. The Company will control the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The investor will pay, in cash, a per-share amount equal to 90% of the average daily closing price of the Company’s stock during the 30 consecutive trading days prior to the issuance of a draw notice, which shall not exceed 400% of the average trading volume for the 30 trading days immediately preceding the draw down date. On June 30, 2021, the Company consummated the Business Combination with LACQ, resulting in the Company’s shares becoming publicly listed on Nasdaq on July 2, 2021. Concurrent with the public listing of the Company’s shares, the Company issued to the investor <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z5hc4Xez0vTb" title="Warrants issued shares">1,106,108</span> warrants with a five-year term to purchase common stock of Ensysce at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp2d_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zsggJD8rMVrl" title="Warrant, exercise price">10.01</span> per share (Note 8). The Company must pay a commitment fee to the investor of $<span id="xdx_90C_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zgB5S44Z2qk2" title="Commitment fees">1.2</span> million with $<span id="xdx_90F_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pp0p0_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--AwardDateAxis__custom--FirstAnniversaryMember_zWWlbVEOKjx8" title="Commitment fees">800,000</span> due on the first anniversary of the public listing date and $<span id="xdx_903_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pp0p0_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--AwardDateAxis__custom--EighteenMonthAnniversaryMember_zxJiNCUoBj1e" title="Commitment fees">400,000</span> due on the 18-month anniversary of the public listing date. The commitment fee can be paid from the proceeds of a draw against the facility or in freely tradable common stock of the Company (Note 11).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2021, the Company entered into a $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20210930__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteFinancingAgreementMember_zoIs9mkAzBX3">15.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million convertible note financing agreement with institutional investors (the “2021 Notes”) (See Note 7 for additional information). In July and August 2022, the Company received funding under a $<span id="xdx_907_eus-gaap--ProceedsFromConvertibleDebt_pn4n6_c20220701__20220731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTvlWXuiTcRc" title="Proceeds from issuance of convertible notes"><span id="xdx_904_eus-gaap--ProceedsFromConvertibleDebt_pn4n6_c20220801__20220809__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2KB0myFgsR6" title="Proceeds from issuance of convertible notes">8.48</span></span> million convertible note financing agreement with the same institutional investors (the “2022 Notes”) (See Note 11 for additional information). The agreements limit the Company’s ability to execute certain debt and equity financings, including its existing $<span id="xdx_908_eus-gaap--CommonStockSharesSubscriptions_iI_pn5n6_c20220731__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteFinancingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhH7CEQk6rnf" title="Share subscription"><span id="xdx_902_eus-gaap--CommonStockSharesSubscriptions_iI_pn5n6_c20220809__us-gaap--TypeOfArrangementAxis__custom--ConvertibleNoteFinancingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoNQtJtnlOO" title="Share subscription">60.0</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million share subscription facility, while the convertible notes are outstanding. Without the availability of proceeds through the share subscription facility, existing cash resources are not sufficient to fund current planned operations. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Cash Cash	7800000	usd
CY2022Q2	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1100000	usd
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.06585
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95500000	usd
CY2020Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	60000000.0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_zxf9UtbkGmqh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zQBBy0PIy3zf">Use of Estimates and Assumptions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, warrants, options to purchase the Company’s common stock, and the notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84A_eus-gaap--ConcentrationRiskCreditRisk_zEoMqpXVuJzi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zv0MdAPWZWeh">Concentrations of credit risk and off-balance sheet risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. The Company has no financial instruments with off-balance sheet risk of loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q2	us-gaap	Depreciation Depreciation	50	usd
	us-gaap	Depreciation Depreciation	101	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	15900000	usd
CY2022Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	2656856	usd
CY2022Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	360797	usd
CY2022Q2	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	3017653	usd
CY2021Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	16799837	usd
CY2021Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	3303588	usd
CY2021Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	20103425	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	20103425	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	-11464566	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-5621206	usd
CY2022Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3017653	usd
CY2018Q3	us-gaap	Grants Receivable GrantsReceivable	5400000	usd
CY2019Q3	us-gaap	Grants Receivable GrantsReceivable	5100000	usd
CY2021Q2	us-gaap	Grants Receivable GrantsReceivable	10700000	usd
CY2019Q3	us-gaap	Grants Receivable GrantsReceivable	5400000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	207471	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	444516	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	810569	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	695091	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7999290	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-935544	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9665976	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1883275	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33988783	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16053550	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30656712	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15943867	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27976155	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4463823	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27432077	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4573506	shares
CY2022Q2	ENSC	Prepaid Research And Development PrepaidResearchAndDevelopment	2359986	usd
CY2021Q4	ENSC	Prepaid Research And Development PrepaidResearchAndDevelopment	2124008	usd
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	681851	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	733234	usd
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	131409	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	74173	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3173246	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2931415	usd
CY2022Q2	ENSC	Share Subscription Facility Commitments Fees ShareSubscriptionFacilityCommitmentsFees	1200000	usd
CY2021Q4	ENSC	Share Subscription Facility Commitments Fees ShareSubscriptionFacilityCommitmentsFees	800000	usd
CY2022Q2	ENSC	Accrued Research And Development AccruedResearchAndDevelopment	747645	usd
CY2021Q4	ENSC	Accrued Research And Development AccruedResearchAndDevelopment	388997	usd
CY2022Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	302519	usd
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	610000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	242050	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	138086	usd
CY2022Q2	ENSC	Accrued Scientific Advisory Board Fees AccruedScientificAdvisoryBoardFees	60032	usd
CY2021Q4	ENSC	Accrued Scientific Advisory Board Fees AccruedScientificAdvisoryBoardFees	60032	usd
CY2021Q4	ENSC	Consultant Stock Compensation Expenses ConsultantStockCompensationExpenses	1342479	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	118345	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	67939	usd
CY2022Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2670591	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3407533	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	360797	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3652790	usd
CY2022Q2	us-gaap	Contractual Obligation ContractualObligation	18600000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	10506	usd
CY2022Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	7834	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	15667	usd
CY2021Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	7062	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	14123	usd
CY2021Q4	ENSC	Consultant Stock Compensation Expenses ConsultantStockCompensationExpenses	1342479	usd
	ENSC	Consultant Compensation Expenses ConsultantCompensationExpenses	125222	usd
CY2022Q2	ENSC	Consultant Compensation Expenses ConsultantCompensationExpenses	38014	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2651074	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	34984	usd
CY2022Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	29202	usd
CY2022Q2	us-gaap	Notes Payable NotesPayable	2656856	usd
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	14032528	usd
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	163517	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2993061	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	17189106	usd
CY2021Q2	ENSC	Stated Interest Accrual StatedInterestAccrual	117817	usd
	ENSC	Stated Interest Accrual StatedInterestAccrual	2004	usd
	ENSC	Stated Interest Accrual StatedInterestAccrual	227197	usd
CY2021Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	771556	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	945969	usd
CY2021Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	889373	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	2004	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1173166	usd
	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	10189772	shares
	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	11198754	usd
CY2022Q2	ENSC	Loss On Debt Conversions LossOnDebtConversions	900000	usd
	ENSC	Loss On Debt Conversions LossOnDebtConversions	2600000	usd
CY2021	ENSC	Proceeds From Financed Insurance Premiums Net ProceedsFromFinancedInsurancePremiumsNet	867300	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.40
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10207306	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2291000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.86
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1357968	shares
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5800000	usd
	ENSC	Termination Of Common Stock Issued TerminationOfCommonStockIssued	500000	shares
	ENSC	Deferred Underwriting Common Stock Issued DeferredUnderwritingCommonStockIssued	125000	shares
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	18901290	shares
CY2021Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2026-06-30
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.50
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.83
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.58
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.96
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.94
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.46
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	361158	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.63
CY2021Q3	ENSC	Debt Instrument Expiration Date DebtInstrumentExpirationDate	2026-09-23
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	722317	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.63
CY2021Q4	ENSC	Debt Instrument Expiration Date DebtInstrumentExpirationDate	2026-11-04
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4444068	shares
	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Grants SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGrants	P7Y7M17D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	46515
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6735068	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.90
	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y10M28D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	46515	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5619542	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.11
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M13D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	6735068	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.90
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y10M28D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	46515	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.96
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	819956	usd
	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Period Expected To Be Recognized SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized	P1Y8M12D
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	28887583	shares

Files In Submission

Name	View Source	Status
0001493152-22-022103-index-headers.html	Edgar Link	pending
0001493152-22-022103-index.html	Edgar Link	pending
0001493152-22-022103.txt	Edgar Link	pending
0001493152-22-022103-xbrl.zip	Edgar Link	pending
ensc-20220630.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
ensc-20220630_lab.xml	Edgar Link	unprocessable
ensc-20220630_def.xml	Edgar Link	unprocessable
ensc-20220630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ensc-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENSC
Ensysce Biosciences, Inc. Stock $ensc

2022 Q3 Form 10-Q Financial Statement

#000149315222022103 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENSC Ensysce Biosciences, Inc. Stock $ensc

2022 Q3 Form 10-Q Financial Statement

#000149315222022103 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENSC
Ensysce Biosciences, Inc. Stock $ensc